Temporary change in MCV4 recommendations

May 30, 2006

Sanofi-Pasteur, manufacturer of the meningococcalpolysaccharide-protein conjugate vaccine (MCV4), has announced ashortage of the vaccine that will last at least through the summerof 2006. Due to the limited supply, CDC is now recommending thatproviders immunize only adolescents at high school entry who havenot previously received MCV4 as well as college freshman living indormitories.

Sanofi-Pasteur, manufacturer of the meningococcal polysaccharide-protein conjugate vaccine (MCV4), has announced a shortage of the vaccine that will last at least through the summer of 2006. Due to the limited supply, CDC is now recommending that providers immunize only adolescents at high school entry who have not previously received MCV4 as well as college freshman living in dormitories. According to the manufacturer, there will be adequate supply to meet demand in these groups. The routine vaccination of children aged 11-12 years with MCV4 should be suspended until the supply improves, according to CDC. The agency recommends that providers track patients who will not be vaccinated, so they may be called back at a later time. Other groups at high risk for meningitis, such as military recruits, should also continue to be vaccinated.

To see more Hot off the Press news articles, click here http://www.drugtopics.com/Hot+off+the+Press.

To go to the Drug Topics homepage, click here http://www.drugtopics.com.